GlassScriptPhysician profile
Edward Jamelarin
NPI 1104024900
$11,662.05
in general payments reported to CMS, 2019-2025
71 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,317 · 2020: $238 · 2021: $520 · 2022: $2,270 · 2023: $2,588 · 2024: $2,428 · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,964 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,963.50 |
| Education | $353.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $976.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $795.59 | 2019-2025 | Enhertu, Lynparza |
| Janssen Biotech, INC. | $644.47 | 2019-2025 | Erleada, Carvykti, Talvey |
| Genentech USA, INC. | $641.71 | 2019-2025 | Tecentriq, Phesgo, Polivy |
| E.R. Squibb & Sons, L.L.C. | $427.54 | 2019-2025 | Opdivo |
| Genzyme Corporation | $422.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $413.89 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $390.05 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $389.38 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Incyte Corporation | $370.52 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $370.47 | 2019-2025 | |
| Abbvie INC. | $367.12 | 2019-2025 | |
| Daiichi Sankyo INC. | $353.54 | 2019-2025 | Enhertu, Datroway |
| Eisai INC. | $339.42 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $286.55 | 2019-2025 | Libtayo |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $276.66 | 2019-2025 | Padcev, Xtandi, Xospata |
| Lilly USA, LLC | $259.98 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Adc Therapeutics America, INC. | $236.44 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $234.51 | 2019-2023 | Imbruvica, Epkinly |
| Shield Therapeutics INC | $216.50 | 2025 | |
| Gilead Sciences, INC. | $206.60 | 2019-2025 | Trodelvy |
| Sobi, INC | $187.81 | 2022-2025 | |
| Array Biopharma INC | $178.57 | 2021-2025 | Braftovi, Lorbrena, Xalkori |
| Takeda Pharmaceuticals U.S.A., INC. | $162.38 | 2019-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Amgen INC. | $152.30 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Ipsen Biopharmaceuticals, INC | $142.75 | 2019-2025 | Onivyde, Tazverik |
| Karyopharm Therapeutics INC. | $139.04 | 2022-2024 | Xpovio |
| Alexion Pharmaceuticals, INC. | $110.62 | 2022-2024 | Ultomiris |
| Rigel Pharmaceuticals, INC. | $109.34 | 2019-2024 | Tavalisse, Rezlidhia |
| Tersera Therapeutics LLC | $104.93 | 2023-2025 | Zoladex |
| Myriad Genetic Laboratories, INC. | $100.11 | 2021-2025 | Precisetumor, Myrisk |
| Emd Serono, INC. | $100.06 | 2019-2023 | Bavencio |
| Exelixis INC. | $93.43 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $89.58 | 2023-2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $77.69 | 2022-2025 | Fotivda |
| Geron Corporation | $77.60 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $77.15 | 2022 | |
| Stemline Therapeutics INC. | $74.90 | 2024-2025 | Orserdu |
| Puma Biotechnology, INC. | $74.85 | 2019-2025 | |
| Beone Medicines USA, INC. | $73.62 | 2025 | Brukinsa |
| Glaxosmithkline, LLC. | $66.25 | 2020-2024 | Jemperli, Zejula |
| Blueprint Medicines Corporation | $63.98 | 2024-2025 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $59.62 | 2019-2020 | |
| Cti Biopharma Corp. | $57.04 | 2022-2023 | Vonjo |
| Myovant Sciences INC. | $50.83 | 2021-2022 | |
| Coherus Oncology, INC. | $50.40 | 2023 | |
| Sun Pharmaceutical Industries INC. | $48.06 | 2022 | |
| Tempus Ai, INC | $45.79 | 2025 | Xt Cdx |
| Ge Healthcare | $40.45 | 2022 | |
| Caris Mpi, INC. | $38.32 | 2025 | Mi Cancer Seek |
| G1 Therapeutics, INC. | $35.00 | 2022 | |
| Mirati Therapeutics, INC. | $34.20 | 2023-2024 | Krazati |
| Morphosys, US INC. | $31.26 | 2022-2023 | Monjuvi |
| Taiho Oncology, INC. | $30.96 | 2019 | |
| Tactile Systems Technology INC | $24.60 | 2019-2025 | Nimbl, Flexitouch Plus |
| Jazz Pharmaceuticals INC. | $21.12 | 2019 | |
| Progenics Pharmaceuticals, INC. | $19.88 | 2024 | |
| Kyowa Kirin, INC. | $17.68 | 2025 | |
| Beigene USA, INC. | $17.48 | 2024 | Brukinsa |
| Teva Pharmaceuticals USA, INC. | $16.56 | 2019 | |
| Springworks Therapeutics, INC. | $16.00 | 2025 | Ogsiveo |
| Genmab U.S., INC. | $15.74 | 2021 | |
| Menarini Silicon Biosystems, INC. | $15.21 | 2024 | |
| Tesaro, INC. | $14.76 | 2019 | |
| Fortovia Therapeutics, INC. | $13.39 | 2019 | |
| Epizyme, INC. | $13.33 | 2022 | |
| Advanced Accelerator Applications | $12.77 | 2020 | |
| Kite Pharma, INC. | $12.46 | 2021 | |
| Dova Pharmaceuticals | $11.98 | 2021 | |
| Verastem, INC. | $11.75 | 2019 | |
| Exact Sciences Corporation | $8.35 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Jamelarin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.